Special medical-purpose formula food for targeted adjuvant therapy of vascular plaque and thrombus

Abstract

The invention discloses a special medical-purpose formula food for targeted adjuvant therapy of vascular plaque and thrombus. Comprising the following raw materials in parts by weight: 300 to 500 parts of corn starch, 100 to 300 parts of tuna oil, 200 to 400 parts of choline chloride, 20 to 80 parts of zinc gluconate, 100 to 400 parts of magnesium chloride, 0.1 to 1.5 parts of active folic acid, 0.01 to 0.03 part of vitamin B12, 1 to 5 parts of vitamin B6, 2 to 10 parts of vitamin B2, 0.01 to 3 parts of TMG, 100 to 200 parts of maltodextrin, 10 to 50 parts of sodium caseinate, 1 to 5 parts of monopotassium phosphate and 1 to 5 parts of silicon dioxide. The invention relates to the technical field of formula foods for special medical purposes, particularly provides a formula food for special medical purposes for targeted adjuvant therapy of vascular plaques and thrombus, specifically adds nutrition beneficial to inhibition of formation of vascular plaques and thrombus, and solves the problem that part of patients are difficult to supplement nutrition through food.

Description

Technical Field

[0001] The present invention relates to the technical field of special medical formula foods, in particular to special medical formula foods for targeted auxiliary treatment of vascular plaques and thrombi. Background Art

[0002] Cardiovascular and cerebrovascular diseases are the chronic diseases with the highest death toll in the world. According to statistics, there are 466 million patients with atherosclerosis in the world, and approximately 19 million new cases of acute myocardial infarction occur worldwide each year, with a mortality rate of 34% to 42%. If patients with acute myocardial infarction or cerebral infarction miss the 6-hour golden thrombolysis period, they may die. Even if the patient survives after treatment, they still have sequelae such as hemiplegia, disability, and hemiplegia. The relative cardiovascular risk of patients 1-5 years after myocardial infarction is at least 30% higher than that of the general population. Vascular plaques are an important pathological basis of cardiovascular disease and an important cause of cardiovascular diseases such as myocardial infarction, cerebral infarction, sudden death, and angina pectoris. Data from the "China Cardiovascular Health and Disease Report 2021" show that the number of cardiovascular disease patients in my country has reached 330 million, and the prevalence of cardiovascular disease is in a continuous rising stage. If vascular plaques can be detected, diagnosed and effectively controlled in the early stages of the disease, effective early prevention and treatment can be provided for the majority of people at risk.

[0003] The formation of vascular plaques and thrombi is a complex and progressive process involving the interaction of multiple factors. The main influencing factors are high blood pressure, high blood lipids, high blood sugar, and high blood sugar. Prevention and treatment require comprehensive intervention for risk factors, including controlling blood pressure, blood lipids, blood sugar, and blood sugar levels, quitting smoking and limiting alcohol, and maintaining a healthy lifestyle. For plaques that have already formed, take measures such as drug therapy, interventional therapy, or surgical treatment according to the specific situation. Among the above influencing factors, recovery can be achieved through drug therapy or nutritional supplementation, but the nutrient content in food is low, and absorption varies from person to person. During clinical treatment, many patients, especially middle-aged and elderly people, are restricted in their food intake and cannot eat a lot of food, or other underlying diseases lead to the inability to absorb nutrients, or their own enzyme activity is reduced or missing, resulting in malnutrition, poor treatment effect, or prolonged treatment cycle. Therefore, choosing special medical purpose formula foods as nutritional supplements for auxiliary treatment is a precise nutritional supplement for patients with the disease. Summary of the invention

[0004] In view of the above situation, in order to make up for the above existing defects, the present invention provides a special medical formula food for targeted auxiliary treatment of vascular plaque and thrombus, which is used to solve the problem that some patients find it difficult to supplement nutrition through food.

[0005] The technical solution adopted by the present invention is as follows: a special medical formula food for targeted auxiliary treatment of vascular plaque and thrombus, comprising the following raw materials in parts by weight:

[0006] 300-500 parts of corn starch, 100-300 parts of tuna oil, 200-400 parts of choline chloride, 20-80 parts of zinc gluconate, 100-400 parts of magnesium chloride, 0.1-1.5 parts of active folic acid, 0.01-0.03 parts of vitamin B12, 1-5 parts of vitamin B6, 2-10 parts of vitamin B2, 0.01-3 parts of TMG, 100-200 parts of maltodextrin, 10-50 parts of sodium caseinate, 1-5 parts of potassium dihydrogen phosphate, and 1-5 parts of silicon dioxide.

[0007] The special medical formula food for targeted auxiliary treatment of vascular plaque and thrombus of the present invention has the best raw materials in parts by weight: including the following raw materials in parts by weight:

[0008] 300 parts of corn starch, 167 parts of tuna oil, 253 parts of choline chloride, 48 parts of zinc gluconate, 218 parts of magnesium chloride, 0.5 parts of active folic acid, 0.01 parts of vitamin B12, 1 part of vitamin B6, 6 parts of vitamin B2, 0.08 parts of TMG, 2 parts of silicon dioxide, 100 parts of maltodextrin, 20 parts of sodium caseinate, and 1 part of potassium dihydrogen phosphate.

[0009] The preparation process of the present invention comprises the following steps:

[0010] S1: prepare tuna oil suspension A, dissolve sodium caseinate and maltodextrin in water to prepare solution B, place tuna oil suspension A and solution B in a high-speed shearing machine, adjust the pH value of the solution to 7.0 with dipotassium hydrogen phosphate, perform shear emulsification, and prepare fish oil emulsion, homogenize the emulsion in a homogenizer at a pressure of 30MPa-40MPa, and obtain fish oil microcapsule liquid after homogenization, spray the fish oil microcapsule liquid evenly into corn starch, and stir at a stirring speed of 25-50rpm for 40-160min to obtain tuna oil microcapsule powder;

[0011] S2: placing the tuna oil microcapsule powder prepared in S1, choline chloride, zinc gluconate, magnesium chloride, active folic acid, vitamin B12, vitamin B6, vitamin B2, and TMG into a mixing mixer, and stirring at a stirring speed of 25-50 rpm for 20-40 minutes to obtain a mixture 1;

[0012] S3: adding silicon dioxide to the mixture 1 prepared in S2, stirring at a stirring speed of 25-50 rpm for 10-15 min to obtain a mixture 2;

[0013] S4: drying the mixture prepared in S3 in a hot air circulation drying oven at 60°C for 8 hours, cooling it, placing it in a mixing mixer, and stirring it at a stirring speed of 25-50 rpm for 10-30 minutes;

[0014] S5: The dried mixture 2 is placed in a granule / powder packaging machine and packaged into food packaging materials with good sealing and light-shielding properties to prepare finished products.

[0015] Furthermore, the preparation process is carried out in an environment with an air humidity of 45-65% and a temperature of 20-24°C.

[0016] In order to facilitate the understanding of the present invention, the raw materials and nutritional values ​​of the present invention are further described below.

[0017] Vitamin B2, vitamin B6, vitamin B12, folic acid, zinc: These nutrients act as methyl carriers or coenzymes and participate in the HCY cycle in the body as specific coenzymes and factors. HCY causes a sharp increase in the incidence of cardiovascular and cerebrovascular diseases. Reducing HCY can reduce the formation of vascular plaques and blood clots.

[0018] Tuna oil: Rich in Omega-3 fatty acids, especially EPA and DHA. Unsaturated fatty acids can promote the health of the circulatory system and prevent the accumulation of cholesterol and fat on the arterial walls. They help lower the levels of bad cholesterol (LDL) and triglycerides in the blood, thereby reducing the risk of atherosclerosis.

[0019] Magnesium: Magnesium plays a key role in maintaining HCY levels. Methionine converts HCY into SAMe, which requires magnesium. If magnesium is deficient, high HCY, low SAMe and low methylation will follow. It can also protect the vascular system and reduce cholesterol deposition in the blood.

[0020] Choline: Choline has affinity for fat, inhibits thrombosis, and prevents the accumulation of lipid substances in blood vessels. Acetylcholine can excite the M1 receptors of the presynaptic ends of noradrenergic nerve endings, inhibit the release of norepinephrine, and produce the effect of vasodilation. At the same time, it can provide methyl groups for the HCY cycle and has a good stabilizing effect on the internal circulation system.

[0021] Active folic acid: Active folic acid has a higher bioavailability than folic acid. For patients with genetic defects in folate cycle enzymes, taking active folic acid and related coenzymes can successfully complete the folic acid cycle metabolism, solving the defect that folic acid cannot be absorbed and utilized by the body in such patients. At the same time, long-term use of active folic acid is safer than folic acid and has no toxic side effects.

[0022] The special medical formula food for targeted auxiliary treatment of vascular plaque and thrombus proposed by the present invention has the following beneficial effects achieved by adopting the above scheme:

[0023] The special medical formula food of the present invention contains tuna oil, which supplements unsaturated fatty acids such as EPA and DHA, enhances the function of white blood cells, improves the body's ability to fight pathogens, regulates the immune system, and improves the body's immunity;

[0024] Essential nutrients for hyperhomocysteinemia, such as vitamin B2, vitamin B6, vitamin B12, folic acid, and zinc, are added as methyl carriers or coenzymes to participate in HCY metabolism. Among them, the use of active folic acid for patients with folate cycle enzyme gene defects solves the problem that folic acid cannot be absorbed and utilized by the body when taken by such patients, and is also safer;

[0025] Adding magnesium plays a key role in maintaining the level of HCY. Adding choline can be fat-affinity and inhibit thrombosis. Acetylcholine can excite the presynaptic M1 receptors of noradrenergic nerve endings, inhibit the release of noradrenaline, and produce the effect of vasodilation. At the same time, it can provide methyl groups for the HCY cycle and has a good stabilizing effect on the internal circulation system.

[0026] Add a variety of nutritional elements that help prevent or assist in the treatment of vascular plaques, and utilize the beneficial effects of various elements to achieve targeted medical nutritional supplementation effects. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 This is the 4-week concentration change diagram of fibrinogen (Fbg), a thrombus indicator in the five groups of models in this protocol;

[0028] Figure 2 This is the 4-week concentration change chart of D-dimer, a thrombotic index in the five groups of models in this protocol;

[0029] Figure 3 This is the 4-week concentration change chart of plasma total cholesterol (TC), a blood lipid index of the five groups in this scheme;

[0030] Figure 4 This is a graph showing the 4-week changes in plasma triglyceride (TG) concentrations for the five groups of model blood lipid indicators in this protocol. DETAILED DESCRIPTION

[0031] The following will clearly and completely describe the technology in the embodiments of the present invention in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all of the embodiments; based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.

[0032] Example 1

[0033] The present embodiment provides a special medical formula food for targeted auxiliary treatment of vascular plaque and thrombosis, including the following raw materials in parts by weight: 300 parts of corn starch, 167 parts of tuna oil, 253 parts of choline chloride, 48 parts of zinc gluconate, 218 parts of magnesium chloride, 0.5 parts of active folic acid, 0.01 parts of vitamin B12, 1 part of vitamin B6, 6 parts of vitamin B2, 0.08 parts of TMG, 2 parts of silicon dioxide, 100 parts of maltodextrin, 20 parts of sodium caseinate, and 1 part of potassium dihydrogen phosphate.

[0034] This embodiment also provides a preparation process of a special medical formula food for targeted auxiliary treatment of vascular plaque and thrombus, comprising the following steps:

[0035] S1: preparing tuna oil suspension A, dissolving sodium caseinate and maltodextrin in water to prepare solution B, placing tuna oil suspension A and solution B in a high-speed shearing machine, adjusting the pH value of the solution to 7.0 with dipotassium hydrogen phosphate, performing shearing emulsification to obtain fish oil emulsion, homogenizing the emulsion in a homogenizer at a pressure of 30MPa-40MPa, and obtaining fish oil microcapsule liquid after homogenization;

[0036] S2: placing choline chloride, zinc gluconate, magnesium chloride, active folic acid, vitamin B12, vitamin B6, and vitamin B2 into a mixing mixer, and stirring at a stirring speed of 25-50 rpm for 10-15 min to obtain a mixture 1;

[0037] S3: spraying the fish oil microcapsule solution prepared in S1 in an equivalent amount into the corn starch uniformly, stirring at a stirring speed of 25-50 rpm for 40-60 min, to obtain a second mixture;

[0038] S4: adding TMG to the mixture 1 prepared in S2 and the mixture 2 prepared in S3, stirring at a stirring speed of 25-50 rpm for 20-40 min to obtain a mixture 3;

[0039] S5: adding silicon dioxide to the mixture 3 prepared in S4, stirring at a stirring speed of 25-50 rpm for 10-15 min to obtain a mixture 4;

[0040] S6: drying the mixture prepared in S5 in a hot air circulation drying oven at 60° C. for 8 h, cooling the mixture, placing it in a mixing mixer, and stirring it at a stirring speed of 25-50 rpm for 10-15 min;

[0041] S7: placing the dried mixture into a granule / powder packaging machine and packaging it into food packaging materials with good sealing and light-shielding properties to prepare finished products.

[0042] The preparation process is carried out in an environment with an air humidity of 45-65% and a temperature of 20-24°C.

[0043] Example 2

[0044] The preparation process of this embodiment is better than that of embodiment 1, and the components thereof are the same.

[0045] The preparation process of this embodiment includes the following steps:

[0046] S1: prepare tuna oil suspension A, dissolve sodium caseinate and maltodextrin in water to prepare solution B; place tuna oil suspension A and solution B in a high-speed shearing machine, and adjust the pH value of the solution to 7.0 with dipotassium hydrogen phosphate; perform shear emulsification to obtain fish oil emulsion, homogenize the emulsion in a homogenizer at a pressure of 30MPa-40MPa, obtain fish oil microcapsule liquid after homogenization, spray the fish oil microcapsule liquid evenly into corn starch, and stir at a stirring speed of 25-50rpm for 40-160min to obtain tuna oil microcapsule powder;

[0047] S2: placing tuna oil microcapsule powder, choline chloride, zinc gluconate, magnesium chloride, active folic acid, vitamin B12, vitamin B6, vitamin B2, and TMG into a mixing mixer, and stirring at a stirring speed of 25-50 rpm for 20-40 minutes to obtain a mixture 1;

[0048] S3: adding silicon dioxide to the mixture 1 prepared in S2, stirring at a stirring speed of 25-50 rpm for 10-15 min to obtain a mixture 2;

[0049] S4: drying the mixture prepared in S3 in a hot air circulation drying oven at 60°C for 8 hours, cooling it, placing it in a mixing mixer, and stirring it at a stirring speed of 25-50 rpm for 10-30 minutes;

[0050] S5: The dried mixture 2 is placed in a granule / powder packaging machine and packaged into food packaging materials with good sealing and light-shielding properties to prepare finished products.

[0051] The preparation process is carried out in an environment with an air humidity of 45-65% and a temperature of 20-24°C.

[0052] Example 3

[0053] S1: placing choline chloride, zinc gluconate, magnesium chloride, active folic acid, vitamin B12, vitamin B6, vitamin B2 and TMG in a mixing mixer, and stirring at a stirring speed of 25-50 rpm for 20-40 min to obtain a mixture 1;

[0054] S2: adding silicon dioxide to the mixture 1 prepared in S1, stirring at a stirring speed of 25-50 rpm for 10-15 min to obtain a mixture 2;

[0055] S3: drying the mixture prepared in S2 in a hot air circulation drying oven at 60°C for 6 hours, cooling it, placing it in a mixing mixer, and stirring it at a stirring speed of 25-50 rpm for 10-30 minutes;

[0056] S4: placing the dried mixture 2 in a granule / powder packaging machine and packaging it into food packaging materials with good sealing and light-shielding properties to prepare finished products;

[0057] The preparation process is carried out in an environment with an air humidity of 45-65% and a temperature of 20-24°C.

[0058] Comparative Example 1

[0059] The tuna oil in Example 2 was replaced with linseed oil, and the remaining operations were the same as in Example 2.

[0060] Comparative Example 2

[0061] The choline and tuna oil in Example 2 were discarded, and the remaining operations were the same as in Example 2.

[0062] Experimental example

[0063] 1. Build an experimental model

[0064] Atherosclerosis (AS) is a chronic progressive disease in which lipid deposition and inflammatory response occur in the arterial intima, forming plaques and progressing to arterial wall damage and thrombosis. It is clinically manifested as coronary heart disease, cerebrovascular disease, lower limb artery disease, etc. The construction of the AS model is consistent with the formation mechanism of arterial vascular plaques. Vascular endothelial damage, platelet aggregation and fibrin deposition are the basis for thrombosis.

[0065] The AS model was constructed by a high-fat diet, and a thrombosis rabbit model was constructed by mechanical injury. After 4 weeks of feeding with a high-fat rabbit feed (containing 1% cholesterol, 7.5% egg yolk powder, 8% lard, 0.5% sodium cholate, 0.1% propylthiouracil and 81% ordinary rabbit feed), it was found that the TC, LDL-C, HDL-C and VLDL of the high-fat fed group were 17.7, 29.2, 4.2 and 25.8 times that of the control group, respectively. Pathology showed that 83% of the rabbit models had early AS, proving that the vascular plaque modeling was successful.

[0066] In order to shorten the thrombosis modeling cycle, after 3-4 weeks of high-fat diet modeling, the vascular endothelium is damaged with a silver needle instrument, which can expose the extracellular matrix under the endothelium of the blood vessels, promote platelets to contact with collagen and be adhered and activated, release tissue factor, further activate endogenous and exogenous coagulation mechanisms, and accelerate thrombosis. The modeling mechanism of this model is very similar to human thrombosis. After 24 hours of mechanical injury modeling, obvious thrombosis angiography can be found in the aorta, coronary artery and other parts.

[0067] 2. Experimental process

[0068] 50 New Zealand rabbits (Article No.: DMZ93Rb02) weighing about 2.5 kg were selected and divided into 5 groups (AE) on average. The rabbit AS model was constructed by the above method for 4 weeks. Since this model did not use ApoE- / - and low-density lipoprotein receptor (LDLR) gene knockout, the animals were considered to have the ability to regulate blood lipids and recovery by themselves. The thrombolytic scheme of intravenous injection of 4 mg / kg·d aspirin was used to investigate the auxiliary effect of the nutritional supplement of the present invention on the recovery period during rehabilitation treatment. Nutritional supplementation and treatment experiments were carried out according to the scheme in Table 1.

[0069] In the experimental feeding, 1.8 g / d of the special medical purpose formula food powder of the present invention was added to the conventional rabbit feed, and 4 mg / kg·d of aspirin was injected intravenously. The evaluation indexes of each experimental group were tested for 4 consecutive weeks.

[0070] Table 1

[0071] Serial number Group Experimental Group 01 A Example 2 02 B Example 3 03 C Comparative Example 1 04 D Comparative Example 2 05 E Blank control

[0072] 3. Evaluation indicators

[0073] During the 4-week experimental period, the experimental rabbits' hallmark thrombosis indicators were checked once a week on average: fibrinogen (Fbg) reflects the body's coagulation function; D-dimer reacts to form thrombi and is released into the blood; and the hallmark blood lipid indicators were examined: plasma total cholesterol (TC) and plasma triglycerides (TG).

[0074] 4. Results Analysis

[0075] Table 2 shows the normal indicators of experimental rabbits;

[0076] Table 2

[0077]

[0078] Table 3 shows the feeding and treatment cycle results of the experimental rabbits.

[0079] Table 3

[0080]

[0081] In the experimental group AE rabbits, after a small dose of aspirin was used to treat thrombosis, the thrombosis indicators fibrinogen (Fbg) and D-dimer showed a downward trend; the blood lipid indicators plasma total cholesterol (TC) and plasma triglyceride (TG) showed a downward trend.

[0082] The experiment showed that the thrombus index fibrinogen (Fbg) in Example 2 showed a greater downward trend than that in other groups, indicating that the index recovery effect was the best. Figure 1 ;

[0083] like Figure 2 As shown, the decreasing trend of D-dimer, a thrombotic index, in Example 2 was greater than that in other groups, indicating that the index recovery effect was the best;

[0084] like Figure 3 As shown, the downward trend of plasma total cholesterol (TC), a blood lipid index in Example 2, was slightly greater than that in other groups, indicating that the index recovery effect was the best;

[0085] like Figure 4 As shown, the downward trend of plasma triglyceride (TG), a blood lipid index in Example 2, was slightly greater than that in other groups, indicating that the index recovery effect was the best;

[0086] Investigate the effect of Example 2 on blood lipid recovery index:

[0087] like Figure 3 and Figure 4 As shown, the blood lipid reduction rate of Example 2 and Comparative Example 1 is faster than that of other groups, because tuna oil is added in Example 2, which is replaced by linolenic acid oil compared with Comparative Example 1. Tuna oil contains EPA, DHA and linolenic acid oil. EPA and DHA unsaturated fatty acids can lower cholesterol in blood vessels and reduce inflammatory factors. Linolenic acid needs to be converted into EPA in the body, and its efficiency is lower than that of tuna oil. Therefore, adding unsaturated fatty acids can promote the transportation and metabolic rate of lipids and cholesterol.

[0088] Investigate the effect of Example 2 on thrombosis recovery indicators:

[0089] like Figure 1-2 As shown, the experimental results of Example 2 and Comparative Example 2 show that by abandoning the use of methyl and tuna oil in nutrients, the rates of reduction of thrombotic indicators and blood lipid indicators are more moderate. Methyl participates in the metabolism of homocysteine ​​in the body, scavenges free radicals and reduces inflammatory factors, and is particularly evident in reducing thrombotic indicators.

[0090] It can be seen from the experimental results in Table 3 that in Example 2, at the 4th week of the treatment cycle, some indicators have returned to normal levels, while other groups have not recovered. The special medical purpose formula food in Example 2 can play a role in targeted auxiliary treatment and shorten the treatment cycle during the drug treatment of experimental rabbits.

[0091] It should be noted that, in this article, relational terms such as first and second, etc. are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Moreover, the terms "include", "comprises" or any other variations thereof are intended to cover non-exclusive inclusion, so that a process, method, material or apparatus including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, material or apparatus.

[0092] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A special medical formula food for targeted auxiliary treatment of vascular plaque and thrombus, characterized by: The raw materials include the following parts by weight: 300-500 parts of corn starch, 100-300 parts of tuna oil, 200-400 parts of choline chloride, 20-80 parts of zinc gluconate, 100-400 parts of magnesium chloride, 0.1-1.5 parts of active folic acid, 0.01-0.03 parts of vitamin B12, 1-5 parts of vitamin B6, 2-10 parts of vitamin B2, 0.01-3 parts of TMG, 100-200 parts of maltodextrin, 10-50 parts of sodium caseinate, 1-5 parts of potassium dihydrogen phosphate, and 1-5 parts of silicon dioxide.

2. The special medical formula food for targeted adjuvant treatment of vascular plaque and thrombus according to claim 1, characterized in that: The raw materials include the following parts by weight: 300 parts of corn starch, 167 parts of tuna oil, 253 parts of choline chloride, 48 parts of zinc gluconate, 218 parts of magnesium chloride, 0.5 parts of active folic acid, 0.01 parts of vitamin B12, 1 part of vitamin B6, 6 parts of vitamin B2, 0.08 parts of TMG, 2 parts of silicon dioxide, 100 parts of maltodextrin, 20 parts of sodium caseinate, and 1 part of potassium dihydrogen phosphate.

3. The method for preparing the special medical formula food for targeted auxiliary treatment of vascular plaque and thrombus according to any one of claims 1-2, characterized in that: S1: prepare tuna oil suspension A, dissolve sodium caseinate and maltodextrin in water to prepare solution B, place tuna oil suspension A and solution B in a high-speed shearing machine, adjust the pH value of the solution to 7.0 with dipotassium hydrogen phosphate, perform shear emulsification, and prepare fish oil emulsion, homogenize the emulsion in a homogenizer at a pressure of 30MPa-40MPa, and obtain fish oil microcapsule liquid after homogenization, spray the fish oil microcapsule liquid evenly into corn starch, and stir at a stirring speed of 25-50rpm for 40-160min to obtain tuna oil microcapsule powder; S2: placing tuna oil microcapsule powder, choline chloride, zinc gluconate, magnesium chloride, active folic acid, vitamin B12, vitamin B6, vitamin B2, and TMG into a mixing mixer, and stirring at a stirring speed of 25-50 rpm for 20-40 minutes to obtain a mixture 1; S3: adding silicon dioxide to mixture 1, stirring at a stirring speed of 25-50 rpm for 10-15 min to obtain mixture 2; S4: drying the mixture in a hot air circulation drying oven at 60°C for 8 hours, cooling it, placing it in a mixing mixer, and stirring it at a stirring speed of 25-50 rpm for 10-30 minutes; S5: The dried mixture 2 is placed in a granule / powder packaging machine and packaged into food packaging materials with good sealing and light-shielding properties to prepare finished products.

4. The method for preparing the special medical formula food for targeted auxiliary treatment of vascular plaque and thrombus according to claim 3, characterized in that: The air humidity during the preparation process is 45-65% and the temperature is 20-24°C.

Images